(Q37866717)

24 August 2017

1 reference

title

Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. (English)

1 reference

24 August 2017

0 references

1 reference

1 reference

1

0 references

language of work or name

English

0 references

publication date

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

53

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

2121-2129

1 reference

A "NEW" ANTIGEN IN LEUKEMIA SERA

24 August 2017

cites work

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

Hepatitis B surface antigen seroclearance during chronic HBV infection

21 January 2018

1 reference

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia

21 January 2018

1 reference

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

21 January 2018

1 reference

Hepatitis B virus biology

21 January 2018

1 reference

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.

21 January 2018

1 reference

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

21 January 2018

1 reference

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

21 January 2018

1 reference

Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

21 January 2018

1 reference

Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers

21 January 2018

1 reference

Hepatitis B surface antigen (HBsAg): a 40-year-old hepatitis B virus seromarker gets new life

21 January 2018

1 reference

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir.

21 January 2018

1 reference

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients

21 January 2018

1 reference

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.

21 January 2018

1 reference

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients

21 January 2018

1 reference

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

21 January 2018

1 reference

HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

21 January 2018

1 reference

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

21 January 2018

1 reference

On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients

21 January 2018

1 reference

Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns.

21 January 2018

1 reference

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

21 January 2018

1 reference

Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir

21 January 2018

1 reference

Hepatitis B virus infection

21 January 2018

1 reference

7 January 2021

A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B

1 reference

7 January 2021

A new role for an old marker, HBsAg

1 reference

7 January 2021

Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy

1 reference

7 January 2021

Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.24364

1 reference

24 August 2017

1 reference